Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1/2
Tests cell therapy and immunotherapy drugs in metastatic melanoma
Tests safety of TIL cell therapy with nivolumab in adults with metastatic melanoma.
Key facts
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Where
- Leiden, NetherlandsSee the site
- Registry title
- ACTME
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 58 people, planned
- Started
- 18 Dec 2024
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 12 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic skin melanoma that has grown despite earlier treatment and cannot be removed by surgery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic skin melanoma, proven by tissue or cell tests. Unresectable stage III or stage IV (AJCC 2009) with normal LDH. Disease that can be measured and is getting worse (RECIST 1.1). Brain metastases are allowed if neurologically stable for at least 2 months and no dexamethasone is used.
- Earlier treatment
- Disease must have progressed on earlier treatment, for example BRAF inhibitors, MEK inhibitors or immunotherapy including anti-PD1. BRAF/MEK inhibitors must have stopped at least 2 weeks before the trial. Immunotherapy must have stopped at least 4 weeks before. Standard treatment options must have failed.
- Biomarker or test result
- Blood tests before surgery must be negative for HIV type 1/2, HTLV and TPHA. No hepatitis B antigen or anti-HBc antibodies, and no hepatitis C antibodies. Blood counts, kidney and liver values must be in the set ranges.
Main reasons for not taking part
- Brain metastases that are neurologically unstable, or use of dexamethasone
- Pregnancy or breastfeeding
- Chronic steroid therapy (10 mg/day prednisone or more) or other immunosuppressive therapy within 14 days before the first dose
- Active immunodeficiency or autoimmune disease needing immune-suppressing drugs
- Another cancer within 2 years (except treated non-melanoma skin cancer and in situ cervical carcinoma)
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age ≥ 18 years
- Able and willing to give valid written informed consent
- Progressive disease on prior treatment with f.e. BRAF-inhibitors, MEK-inhibitors or immunotherapy, including anti-PD1 treatment. Systemic therapy with BRAF-/MEK-inhibitors must have been discontinued for at least two weeks before start of study treatment. Treatment with immunotherapy must have been discontinued for at least four weeks before start of study treatment
- Histologically or cytologically proven metastatic skin melanoma
- Melanoma must be at one of the following AJCC 2009 stages: - Unresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification unresectable stage III melanoma, or- Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH - Patients have failed on standard treatment options
- Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone
- Presence of measurable progressive disease according to RECIST version 1.1
- Expected survival of at least 3 months
- WHO performance status ≤1
- Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified: Lab Parameter Range Hemoglobin ≥ 6,0 mmol/l Granulocytes ≥ 1,500/μl Lymphocytes ≥ 700/μl Platelets ≥ 100,000/μl Creatinine clearance ≥ 60 min/ml Serum bilirubin ≤ 40 μmol/l ASAT and ALAT ≤ 5 x the normal upper limit LDH ≤ 2 x the normal upper limit
- Viral tests must be performed at least 30 days before surgery: - Negative for HIV type 1/2, HTLV and TPHA - No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum - No antibodies against HCV (hepatitis C virus) in the serum
Who cannot take part
- Patients with brain metastases who are neurologically unstable and/or use dexamethasone
- Subjects with a condition requiring systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) orany immunosuppressive therapy within 14 days prior to planned date for first dose of study treatment. Topical,inhaled, nasal and ophthalmic steroids, and adrenal replacement therapy are allowed
- Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or otherconditions requiring concurrent medications not allowed during this study
- Active immunodeficiency disease, autoimmune disease requiring immune suppressive drugs or autoimmune adverse events following treatment with checkpoint inhibitors. Vitiligo is not an exclusion criterion
- Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma
- Known allergy to penicillin or streptomycin (used during the culturing of T cells)
- Clinically significant heart disease (NYHA Class III or IV)
- Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
- Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the associated with the participation, study drug administration, or would impair the ability of the patient to receive protocol therapy
- Lack of availability for follow-up assessments
- Pregnancy or breastfeeding
Where in Netherlands
- LUMCLeiden, NetherlandsTaking people
About the trial
What the trial wants to find out
Evaluating the safety and toxicity of first TIL and nivolumab and later of the combinatiën of TIL, PEG-IFNa and nivolumab based on the CTCAE 4.0 criteria
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- (ACTME) Adoptive TIL therapy with low-dose PEG-IFNa plus nivolumab in metastatic melanoma
- Plain-language title
- Tests cell therapy and immunotherapy drugs in metastatic melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 August 2025